Peptide CDMO Evaluation Criteria: 2026 Reality Check

What the 2026 Capacity Picture Actually Tells a Buyer

Capacity announcements describe a supplier’s plan, not a slot you can book. Bachem’s own half-year disclosure makes the distinction concrete: EBIT fell 19.1% to CHF 54.1 million, and the EBIT margin compressed to 16.6% from 21.4% a year earlier, with Building K ramp-up costs cited as the cause (Bachem Holding AG, ad-hoc release, 2026-07-30).

The CMC Development versus Commercial API split shows why a single growth headline misleads. In H1 2026, CMC Development reached CHF 167.5 million (+39.5% in local currencies) while Commercial API fell to CHF 133.0 million (-19.3% LC), and Research & Specialties added CHF 25.9 million (+30.5% LC) (same release, 2026-07-30). Growth is not uniform across the lifecycle, so the segment a supplier is expanding tells you which customers it is prioritizing.

Read the guidance the same way. The original full-year 2025 guidance set 35% to 45% local-currency growth with CAPEX above CHF 400 million for 2026 (Bachem Holding AG, ad-hoc release, 2026-03-12), later narrowed to 35% to 40%. And Bachem’s CEO on planning security is explicit that long-term collaborations “enable us to reliably plan the development and utilization of production capacities” (Bachem, 2023-03-02). Building K’s 2026 start-up, already manufacturing commercial GMP products alongside CHF 148.4 million of H1 investment, is supplier-side planning (Bachem Holding AG, ad-hoc release, 2026-07-30).

So treat these figures as questions, not proof. The rest of this guide turns them into six peptide CDMO evaluation criteria: needs assessment, technical breadth, modification expertise, analytical depth, communication and lead times, and the exploratory-to-process-development transition.

Needs Assessment: What You Are Actually Buying Before You Compare Suppliers

Peptide CDMO evaluation criteria only work once you have classified your own program, because stage, scale, modality, modification route and analytical obligation each change what a credible supplier must be able to show. Buyers who open with a supplier comparison usually end up comparing marketing pages rather than capability.

Start with five questions. What development stage is the material for: exploratory synthesis, clinical supply, or commercial GMP? What scale must the route survive, and does it have to hold across the full range rather than at one point? Which modality applies: linear peptide, modified or conjugated peptide, or something oligonucleotide-adjacent? Does the modification happen on-resin or in solution, and does it involve non-natural residues or a conjugate? Finally, what is the analytical obligation: research-grade release, or a specification that will be filed and defended?

A supplier’s segment mix is a useful signal of which of these it is built to serve. Bachem’s half-year 2026 results reported group sales of CHF 326.4 million, up 4.3% in CHF and 7.3% in local currencies (Bachem’s half-year 2026 results, 2026-07-30), and the segment mix in Bachem’s H1 2026 disclosure shows where that revenue concentrates. Bachem’s own capability positioning describes full-lifecycle peptide and oligonucleotide API support across four GMP-certified sites, while MOL Changes’ synthesis platforms cover SPPS, liquid-phase, hybrid and fermentation routes across a milligram-to-kilogram range.

Key Takeaway: Answer the five classification questions before you request quotes. Stage, scale, modality, modification and analytical obligation decide which suppliers are even comparable.

Technical Breadth: Reading a Capability Claim at the Right Resolution

Peptide CDMO technical capabilities are only meaningful when a supplier states them as a sequence length, a chemistry and a scale. “Complex peptides” is not a specification. Ask for the number.

The practical ladder starts with routine solid-phase synthesis, which is generally reliable to roughly 30 to 40 residues. Beyond that range, coupling efficiency falls sharply for sequence-dependent reasons, which is why the ceiling moves between projects rather than sitting at one fixed number.

A 2026 Nature Chemistry study on on-resin aggregation explains the mechanism: aggregation typically begins within 5 to 15 amino acids of the resin anchoring point, so C-terminal residues exert the greatest influence, and fractional amino-acid composition rather than exact sequence largely determines behaviour. The failure is structural, not operator error.

That makes the answers measurable. The documented Arg-tag purity improvement took crude purity on polystyrene resin from about 20% to 41%, and a difficult peptide aggregating around Ser10 produced poor crude product with many deletion impurities until backbone protection was applied.

So ask four things: which sequences you have failed on, your longest routine length, your documented mitigation for aggregation-prone stretches (backbone protection, pseudoproline, microwave, HFIP), and the crude purity you see before purification.

Modification Expertise: Where the Route Decision Gets Made

Complex peptide modification services are not a menu of chemistries. They are the ability to choose a site of modification and defend that choice against the impurity profile it creates.

The route decision comes first. On-resin modification adds fewer steps, but it exposes the modification to every subsequent coupling and deprotection, so side reactions accumulate into the final profile. In-solution modification after cleavage gives cleaner control over the modified species, at the cost of an extra purification and a scale-up step. Neither is universally better; the program’s scale and the modification’s stability decide it.

Classes fail differently. Non-natural residues and N-methylation change coupling kinetics and can drive deletion sequences. Lipidation and PEGylation introduce hydrophobic or polymeric species whose removal, not whose attachment, is usually the hard part. The point at which a modification choice locks in the impurity profile is the route decision itself, not the final purification.

Ask three questions of every supplier. Which modifications do you perform in-house versus outsource, and how does that split change your analytical package? At what scale does your preferred route change? What happens to the route when the program moves from feasibility to GMP? MOL Changes’ modification portfolio states more than 300 modifying groups, including isotope labelling, N- and C-terminal modifications, glycopeptides, cyclic peptides, biotinylation and fluorescent labelling, which is the kind of scope claim worth testing against those three questions. Bachem’s own capability positioning is a useful comparison point for how a supplier draws its in-house versus outsourced boundary.

Analytical Depth: The Criteria That Decide a Due-Diligence Call

Peptide analytical method development is where a supplier’s dossier stops being a certificate of analysis and becomes a control strategy. A CoA reports one lot against one specification. A control strategy explains how that specification was set, what the method can and cannot detect, and what happens when the method is transferred to your laboratory or to a GMP site.

Ask for orthogonal characterization: reversed-phase HPLC plus mass spectrometry plus a second separation that works by a mechanistically different principle, so a co-eluting impurity cannot hide behind the main peak. Ask how impurity profiling is judged against the ICH Q3A/Q3B impurity thresholds applied to peptides, where reporting begins at 0.05%, identification at 0.10% and qualification at 0.15% for a drug substance at a maximum daily dose of 2 g/day or less. The widely quoted 95% to 98% purity by RP-HPLC is an industry convention, not a compendial limit; USP monographs set criteria per monograph.

Method validation should follow ICH Q2(R2) as published in March 2024, which covers spectroscopic procedures and post-approval change management. Sterility testing and USP <85> bacterial endotoxins testing are separate gates: a lot can pass one and fail the other, and the Gel Clot Limit Test is the referee method in a dispute. ISO 9001:2015 and ISO 13485:2016 certify quality management systems, not peptides or APIs; ICH Q7 remains the GMP baseline.

Communication and Lead Times: What the Contract Actually Protects

Ask any peptide CDMO evaluation to give you three separate numbers, because they are three different commitments: the quoted lead time, the protected slot, and the realistic first-GMP-batch date. A quoted lead time is an estimate. A protected slot is a contractual reservation of manufacturing capacity. The realistic first-batch date is the one your IND milestone actually depends on, and it is the one most often left implicit.

What separates a supplier that protects your slot from one that merely describes it is what sits in writing. Four clauses carry most of the weight: the change-control notification window, the named technical contact and their stated availability, the escalation path when something slips, and the batch-record and deviation-notification obligations. Add one more question: what happens to your slot if it slips. A supplier’s own long-term contracts exist to secure its capacity planning, which is Peptide a legitimate business interest but not the same as protecting your reservation. Bachem’s long-term follow-on peptide supply contract, signed in March 2023, commits a minimum CHF 1 billion in total order volume across 2025 to 2029, with the customer unnamed and confidentiality agreed. That structure tells you how the supplier plans capacity; it does not tell you how it treats yours. Cem Peptide Synthesizer

Key Takeaway: Get three numbers in writing, not one. Quoted lead time, protected slot, and realistic first-GMP-batch date. Then lock four clauses: change-control notification window, named technical contact and availability, escalation path, and deviation-notification obligations. Peptide 1

Widely circulated figures of 9 to 18 months, or 18 to 24 months, for CDMO engagement timelines are unconfirmed trade-source claims, not benchmarks. Build your own timeline from the committed dates the supplier puts in the contract, and treat any number you cannot trace to a signed commitment as an estimate.

From Exploratory Synthesis to Process Development: Where Programs Actually Break

Peptide process development scale-up is where most programs lose time, and the loss rarely announces itself as a phase gate. It shows up as a sequence of small events. Feasibility synthesis at 0.1 mmol proves the sequence can be made at all. The chosen route then meets mixing, heat transfer and reagent addition rates that change the impurity profile, and an aggregation-prone sequence that behaved at bench scale can fail at 10 mmol. Analytical methods transfer next, and a method validated on a small-scale crude does not automatically hold on a larger batch. The specification set at feasibility may not be the specification that can be filed.

Three failure modes recur: aggregation and deletion impurities that surface only at scale, on-resin modifications that cannot be reproduced in solution, and method-transfer gaps discovered at the first GMP batch. Each one is cheaper to find before the route is locked.

This is also where a supplier’s structure becomes visible. A CDMO that hands work between a research group and a GMP group will answer scale-up questions in two voices. MOL Changes’ synthesis platforms, which the company states span solid-phase and liquid-phase synthesis plus modification with in-house HPLC/MS and sterility QC, is a capability claim worth testing against exactly these three failure modes rather than accepting as a summary.

Red Flags and Deal-Breakers: Separating Fixable Gaps From Disqualifiers

In peptide CDMO evaluation criteria, the useful split is not “good supplier versus bad supplier” but “gap I can manage versus condition that disqualifies.” The distinction is commercial, not academic: a deal-breaker cannot be fixed by a better price, while a manageable gap priced as a deal-breaker is a negotiation position rather than a technical finding.

Deal-breakers are structural. No ICH Q7 GMP evidence for the specific site that will make your material disqualifies a supplier, because ICH Q7 is the baseline expectation for API manufacture and a certificate held by a different plant does not transfer. The same applies to absent in-house orthogonal characterization, refusal to name the site and team that will run your program, no documented change-control process, and a CoA reporting one purity number with no impurity profile.

Manageable gaps look different. A longer quoted lead time with a protected slot, a modification currently outsourced behind a named partner and transfer plan, or a method needing development with a documented validation path under ICH Q2(R2) are all workable, provided the commitment is written into the contract.

Red flags: deal-breaker or manageable gap?

| Condition | Verdict | The question that decides it | | No ICH Q7 GMP evidence for your manufacturing site | Deal-breaker | Is the certificate for the site that will make my batch? | | No in-house orthogonal characterization | Deal-breaker | Can they characterize what they cannot see? | | Site and team unnamed | Deal-breaker | Who signs the batch record? | | No documented change-control process | Deal-breaker | What happens when a raw-material source changes? | | CoA shows one purity number, no impurity profile | Deal-breaker | What is in the other percent? | | Longer lead time, protected slot | Manageable | Is the slot contractually reserved? | | Modification outsourced, partner named | Manageable | Is there a dated transfer plan? | | Method needs development, validation path documented | Manageable | Is the ICH Q2(R2) path agreed in writing? |

Strategic announcements are not auditable capability. Bachem’s Sisslerfeld announcement commits more than CHF 500 million to a greenfield large-scale facility with commercial production expected in 2030, and the partnership details were not disclosed by agreement. That signals direction, not a qualification you can inspect today.

How to Use These Criteria to Decide

Score the six dimensions against your own needs assessment, not against each other. A supplier that leads on modification breadth can still be the wrong choice if your program needs process development scale-up support and their evidence there is thin. Weight each dimension by how much it matters for your molecule and stage, then compare only like-for-like evidence.

A short procedure works better than a long one. Assign each dimension a weight that sums to 100. Request the same evidence package from every supplier: impurity profile method and limits, route rationale, quoted lead time with the conditions attached, and the analytical methods that will transfer with the program. Then treat unanswered questions as negative evidence rather than neutral. A supplier who cannot describe how a 40-residue hydrophobic sequence is handled has told you something.

Read public disclosure correctly. Bachem’s half-year 2026 results and its 2026 investment guidance, including CHF 350–400 million of planned investment and sales growth guidance of 35% to 40% in local currencies (Bachem Holding AG, 2026-07-30), signal strategic direction. Building K’s 2026 start-up signals the same. Neither is auditable evidence of technical performance on your sequence, so use them to judge where a supplier is investing, not what it can do for you.

The next step is to test these peptide CDMO evaluation criteria against a real program: talk to a technical expert about your sequence and stage, and compare capabilities on the evidence that matters.

Frequently Asked Questions

What should I ask a peptide CDMO on a first technical call?

Ask for the route, not the pitch: which synthesis platform the team would choose for your sequence and why, who owns the analytical methods, and what happens if the sequence fails at scale. ICH Q7 sets the API GMP baseline those answers sit inside, so ask which parts of the work run under it.

Is a capacity expansion evidence of capability?

Nee. Announced capacity shows a company expects demand, not that the site can run your chemistry. Judge capability separately, on route selection, impurity control and the analytical package, and treat capacity as a scheduling input.

How long does peptide CDMO engagement realistically take?

Published figures vary widely and are divergent estimates, not settled numbers. Timelines depend on sequence difficulty, whether methods already exist, and queue position, so ask for a quoted lead time, a protected slot and a realistic first-GMP-batch date as three separate commitments.

How do I compare a CoA across two suppliers?

Compare the method, not just the number: which impurities were measured, against which thresholds, by which technique. ICH Q3A/Q3B impurity thresholds applied to peptides define the reporting and qualification limits, and ICH Q2(R2) as published in March 2024 covers how the validating method itself is demonstrated. A CoA without method detail is not comparable.

Does ISO certification substitute for GMP evidence?

Nee. ISO covers a management system; GMP evidence covers how the material was made and controlled. Ask against ICH Q7, and require endotoxin data traceable to a defined method such as USP <85> bacterial endotoxins testing.

What purity specification is reasonable for a clinical-stage peptide?

It depends on the indication, route and phase, and no single number fits every program. Ask the CDMO to justify the specification against the impurity profile and the toxicology batch rather than quoting a default, and confirm the release and stability methods are validated for it.

How is GLP-1 demand changing peptide CDMO lead times?

It is tightening them, but the size of the effect is contested. Morgan Stanley’s GLP-1 market outlook puts 2025 GLP-1 sales at USD 79 billion and a base case of USD 190 billion by 2035, while Grand View Research’s peptide therapeutics forecast projects USD 294.58 billion by 2033 at 8.73% CAGR. A second house’s peptide market estimate is far lower, so treat the demand signal as directionally real and the magnitude as an open question.

Conclusion

The most useful shift a buyer can make is to treat reported capacity as an input to interrogate rather than as evidence of fit, and peptide CDMO evaluation criteria exist precisely to make that interrogation repeatable. Start with your own requirements, then read technical breadth at the resolution of the actual route, weigh modification and analytical depth against the chemistry you need, and test what the contract protects rather than what the brochure promises. The market’s own estimates diverge widely, with Grand View Research projecting USD 294.58 billion by 2033 against Mordor Intelligence’s USD 70.20 billion by 2031, a gap that reflects different market definitions as much as different forecasts. That divergence is the argument for checkpoints over narrative. It also cuts the other way on timing: capacity announced for 2030, such as Bachem’s Sisslerfeld announcement, is not capacity available to a 2026 program. MOL Changes has a commercial interest in peptide quality standards.